Article
Raymond James Downgrades Tvardi Therapeutics to Market Perform
Raymond James analyst Ryan Deschner downgrades Tvardi Therapeutics (NASDAQ:TVRD) from Outperform to Market Perform.
Comments
- No comments yet. Be the first to comment!